Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CHIEF MEDICAL OFFICER

COO & CBO

GENERAL COUNSEL & CORP SEC

Chief Medical Officer

General Counsel & Corp Sec

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic di...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-17	Premium	sold	Premium	Premium	Premium	-
2024-04-01	Premium	acquired	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-04-01	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-04-01	Premium	sold	Premium	Premium	Premium	COO & CBO
2024-04-01	Premium	acquired	Premium	Premium	Premium	COO & CBO
2024-03-28	Premium	sold	Premium	Premium	Premium	GENERAL COUNSEL & CORP SEC
2024-03-19	Premium	sold	Premium	Premium	Premium	CFO
2024-03-19	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-03-19	Premium	sold	Premium	Premium	Premium	COO & CBO
2024-03-19	Premium	sold	Premium	Premium	Premium	CEO
2024-03-19	Premium	sold	Premium	Premium	Premium	GENERAL COUNSEL & CORP SEC
2024-03-15	Premium	acquired	Premium	Premium	Premium	COO & CBO
2024-03-15	Premium	acquired	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-03-15	Premium	acquired	Premium	Premium	Premium	CFO
2024-03-15	Premium	acquired	Premium	Premium	Premium	CEO
2024-03-15	Premium	acquired	Premium	Premium	Premium	GENERAL COUNSEL & CORP SEC
2024-03-01	Premium	acquired	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-03-01	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-02-13	Premium	acquired	Premium	Premium	Premium	-
2024-02-01	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-01-02	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-07-03	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-06-21	Premium	sold	Premium	Premium	Premium	General Counsel & Corp Sec
2023-06-01	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-05-04	Premium	sold	Premium	Premium	Premium	Chief Medical Officer

STOK - Stoke Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for STOK